Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 177 of the 177 references it cites were found in a registry or an index.

Fragile X and autism: Intertwined at the molecular level leading to targeted treatments

Open access
Hagerman, Randi, Hoem, Gry, Hagerman, Paul · 2010 · Molecular Autism

Abstract

Fragile X syndrome (FXS) is caused by an expanded CGG repeat (> 200 repeats) in the 5' untranslated portion of the fragile mental retardation 1 gene (FMR1), leading to deficiency or absence of the FMR1 protein (FMRP). FMRP is an RNA carrier protein that controls the translation of several other genes that regulate synaptic development and plasticity. Autism occurs in approximately 30% of FXS cases, and pervasive developmental disorder, not otherwise specified (PDD-NOS) occurs in an additional 30% of cases. Premutation repeat expansions (55 to 200 CGG repeats) may also give rise to autism spectrum disorders (ASD), including both autism and PDD-NOS, through a different molecular mechanism that involves a direct toxic effect of the expanded CGG repeat FMR1 mRNA. RNA toxicity can also lead to aging effects including tremor, ataxia and cognitive decline, termed fragile X-associated tremor ataxia syndrome (FXTAS), in premutation carriers in late life. In studies of mice bearing premutation expansions, there is evidence of early postnatal neuronal cell toxicity, presenting as reduced cell longevity, decreased dendritic arborization and altered synaptic morphology. There is also evidence of mitochondrial dysfunction in premutation carriers. Many of the problems with cellular dysregulation in both premutation and full mutation neurons also parallel the cellular abnormalities that have been documented in autism without fragile X mutations. Research regarding dysregulation of neurotransmitter systems in FXS, including the metabotropic glutamate receptor (mGluR)1/5 pathway and γ aminobutyric acid (GABA)A pathways, have led to new targeted treatments for FXS. Preliminary evidence suggests that these new targeted treatments will also be beneficial in non-fragile X forms of autism.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/2040-2392-1-12

Cites

177 of 177 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Overview of the behavioral/cognitive phenotype of fragile X syndrome (FXS). The interrelationships among cognitive, behavioral and attentional deficits in FXS are modified by additional environmental influences and genetic background effects. Environmental influences include seizures, trauma, abuse and socioeconomic status. Genetic influences include allelic variations, additional genetic disorders and variation in the expression levels of genes important for the phenotype of FXS.
Figure 1 Overview of the behavioral/cognitive phenotype of fragile X syndrome (FXS). The interrelationships among cognitive, behavioral and attentional deficits in FXS are modified by additional environmental influences and genetic background effects. Environmental influences include seizures, trauma, abuse and socioeconomic status. Genetic influences include allelic variations, additional genetic disorders and variation in the expression levels of genes important for the phenotype of FXS.CC BY · PubMed Central
Figure 2 Molecular overlap between autism, fragile x syndrome (FXS) and premutation disorders. Absence of the FMR1 protein (FMRP) leads to the dysregulation of several proteins including those involved with synapse formation and plasticity, glutamate and γ aminobuyric acid (GABA) neurotransmission and mammalian target of rapamycin (mTOR) and phosphatase and tensin homolog (PTEN) pathways. A premutation is associated with elevation of FMR1 mRNA, leading to sequestration of proteins and mitochondrial dysfunction. Many of these same molecular changes can also occur in some types of autism. Some patients with FXS have mosaicism of premutation and full cells, so there is overlap of the molecular mechanisms among all three disorders.
Figure 2 Molecular overlap between autism, fragile x syndrome (FXS) and premutation disorders. Absence of the FMR1 protein (FMRP) leads to the dysregulation of several proteins including those involved with synapse formation and plasticity, glutamate and γ aminobuyric acid (GABA) neurotransmission and mammalian target of rapamycin (mTOR) and phosphatase and tensin homolog (PTEN) pathways. A premutation is associated with elevation of FMR1 mRNA, leading to sequestration of proteins and mitochondrial dysfunction. Many of these same molecular changes can also occur in some types of autism. Some patients with FXS have mosaicism of premutation and full cells, so there is overlap of the molecular mechanisms among all three disorders.CC BY · PubMed Central
Figure 3 Potential mechanisms of FMR1 mRNA toxicity. Although numerous studies point to RNA toxicity as the underlying pathogenic trigger in fragile X-associated tremor ataxia syndrome (FXTAS), the specific mechanism for such toxicity is not known. Possibilities include (1) sequestration of one or more proteins that bind to the RNA, thus attenuating their other cell functions; (2) protein activation upon binding to the CGG-repeat RNA, leading to dysregulation of one or more signaling cascades; and (3) various co-transcriptional process, such as R-loop formation, that lead to DNA damage/repair signaling and consequent cellular dysregulation.
Figure 3 Potential mechanisms of FMR1 mRNA toxicity. Although numerous studies point to RNA toxicity as the underlying pathogenic trigger in fragile X-associated tremor ataxia syndrome (FXTAS), the specific mechanism for such toxicity is not known. Possibilities include (1) sequestration of one or more proteins that bind to the RNA, thus attenuating their other cell functions; (2) protein activation upon binding to the CGG-repeat RNA, leading to dysregulation of one or more signaling cascades; and (3) various co-transcriptional process, such as R-loop formation, that lead to DNA damage/repair signaling and consequent cellular dysregulation.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 175 references

Research works printed but not linked: 6

  1. Nishimura Y Martin CL Vazquez-Lopez A Spence SJ Alvarez-Retuerto AI Sigman M Steindler C Pellegrini S Schanen NC Warren ST Geschwind DH Genome-wide expression profiling of lymphoblastoid cell lines distinguishes different forms of autism and reveals shared pathways Hum Mol Genet 2007 16 1682 1698 10.1093/hmg/ddm116 17519220 · DOI · Paper page
  2. Sellier C Hagerman P Willemsen R Charlet-Berguerand N DROSHA/DGCR8 sequestration by expanded CGG repeats leads to global micro-RNA processing alteration in FXTAS patients [abstract] 12th International Fragile X Conference; July 21-25; Detroit, MI 2010
  3. Aziz M Stathopulu E Callias M Taylor C Turk J Oostra B Willemsen R Patton M Clinical features of boys with fragile X premutations and intermediate alleles Am J Med Genet 2003 121B 119 127 10.1002/ajmg.b.20030 12898586 · DOI
  4. Farzin F Perry H Hessl D Loesch D Cohen J Bacalman S Gane L Tassone F Hagerman P Hagerman R Autism spectrum disorders and attention-deficit/hyperactivity disorder in boys with the fragile X premutation J Dev Behav Pediatr 2006 27 S137 144 10.1097/00004703-200604002-00012 16685180 · DOI · Paper page
  5. Miyashiro KY Beckel-Mitchener A Purk TP Becker KG Barret T Liu L Carbonetto S Weiler IJ Greenough WT Eberwine J RNA cargoes associating with FMRP reveal deficits in cellular functioning in Fmr1 null mice Neuron 2003 37 417 431 10.1016/S0896-6273(03)00034-5 12575950 · DOI · Paper page
  6. Kooy F Heulens I D'Hulst C Van der Aa N Bagni C Hassan B De Deyn P The GABAA receptor as a potential target for therapy of the fragile X syndrome [abstract] NFXF 12th International FX Conference; July 21 - 25; Detroit, MI 2010

Cited by

See all 256

Metadata

Authors
Hagerman, R., Hoem, G., & Hagerman, P.
Affiliations
  • University of California Davis Medical Center (US)
  • UiT The Arctic University of Norway (NO)
  • University of California, Davis (US)
Corresponding author
Hagerman, Randi
Venue
Molecular Autism
Published
2010
Volume
1
Issue
1
Pages
12
ISSN
2040-2392 (ISSN-L)
OpenAlex
W2099899772
Cited by
247
References
175
Citations by year
2026: 4 · 2025: 10 · 2024: 7 · 2023: 4 · 2022: 12 · 2021: 19 · 2020: 5 · 2019: 12 · 2018: 8 · 2017: 14 · 2016: 22 · 2015: 16 · 2014: 33 · 2013: 32 · 2012: 28
FWCI
14.56
Type
journal article
Language
en
Open access
Licence
cc-by
Locations
  • Molecular Autism (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
  • eScholarship (California Digital Library) (submittedVersion)
Funders
  • Norges Forskningsråd
  • National Institute on Aging (RL1AG032115)
  • National Institute of Dental and Craniofacial Research (UL1DE019583)
  • National Center for Research Resources (HD02274, AG032115, AG032119, HD036071, 90DD05969, UL1RR024146, DE019583, DA024854)
  • Eunice Kennedy Shriver National Institute of Child Health and Human Development (R01HD036071)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetics and Neurodevelopmental Disorders
  • Life Sciences › Neuroscience › Cognitive Neuroscience › Autism Spectrum Disorder Research
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Genetic Neurodegenerative Diseases
Keywords
fragile X syndrome, autism spectrum disorder, FMR1 gene, CGG repeat expansion, FMRP, fragile X premutation, fragile X-associated tremor/ataxia syndrome, RNA toxicity, synaptic development, mitochondrial dysfunction, GABAA receptor, targeted therapy, pervasive developmental disorders

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Fragile X and autism: Intertwined at the molecular level leading to targeted treatments. https://app.cochat.ai/papers/10.1186/2040-2392-1-12
The paper
Hagerman, R., Hoem, G., & Hagerman, P. (2010). Fragile X and autism: Intertwined at the molecular level leading to targeted treatments. Molecular Autism. https://doi.org/10.1186/2040-2392-1-12

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.